225Ac-DOTA-Anti-CD38 monoclonal antibody (daratumumab radiolabeled with Actinium-225)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for 225Ac-DOTA-Anti-CD38 monoclonal antibody (daratumumab radiolabeled with Actinium-225), covering 2025-07-29 to 2025-07-29. Get the full timeline:
Most recent: Clinical Trial Update: 225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody With Fludarabine, Melphalan and Total Marrow and Lymphoid Irradiation as Conditioning Treatment for Donor Stem Cell Transplant in Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome [Phase 1]